Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction

Beltrami, Matteo; Ruocco, Gaetano; Franci, Beatrice; Lucani, Barbara; Aloia, Elio; Nuti, Ranuccio; Palazzuoli, Alberto

doi:10.1016/j.cca.2016.04.007

Cited by 31 publications

(22 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Galectin-3 expression levels demonstrated no difference between patients with HFpEF or HFrEF. However, it was associated with diastolic dysfunction severity and LV stiffness in patients with HFpEF, and associated with poor clinical outcome(s) independent of renal dysfunction and other risk factors in patients with HFpEF ( 39 ). Furthermore, for patients with compensated systolic HF undergoing treatment, galectin-3 demonstrated no association with eGFR, LVEF or functional capacity ( 40 ).…”

Section: Galectin-3 and Cardiovascular Diseasementioning

confidence: 99%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, which are β-galactoside-binding lectins with ≥1 evolutionary conserved carbohydrate-recognition domain. It binds proteins in a carbohydrate-dependent and -independent manner. Galectin-3 is predominantly located in the cytoplasm; however, it shuttles into the nucleus and is secreted onto the cell surface and into biological fluids including serum and urine. It serves important functions in numerous biological activities including cell growth, apoptosis, pre-mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Numerous previous studies have indicated that galectin-3 may be used as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease and cancer. With emerging evidence to support the function and application of galectin-3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin-3 in associated diseases.

show abstract

Section: Galectin-3 and Cardiovascular Diseasementioning

confidence: 99%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Furthermore, some cytokines have been reported to promote cardiac fibrosis in ageing directly. Galectin‐3, promotes collagen synthesis, deposition, and fibrosis by regulating MMPs/TIMPs levels, as well as independently predicting all‐cause mortality . Cardiotrophin‐1 is a cytokine related to cardiac hypertrophy which promotes fibrosis through upregulating fibrogenic factors (TIMP‐1, osteopontin and periostin), down‐regulating anti‐fibrotic factors (MMP‐2 and MMP‐13), and inducing fibroblast proliferation and/or differentiation .…”

Section: Contributors Of Cardiac Fibrosis In Ageingmentioning

confidence: 99%

Cardiac fibrosis in the ageing heart: Contributors and mechanisms

Guo

Yue

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Cardiac fibrosis refers to an excessive deposition of extracellular matrix (ECM) in cardiac tissue. Fibrotic tissue is stiffer and less compliant, resulting in subsequent cardiac dysfunction and heart failure. Cardiac fibrosis in the ageing heart may involve activation of fibrogenic signalling and inhibition of anti-fibrotic signalling, leading to an imbalance of ECM turnover. Excessive accumulation of ECM such as collagen in older patients contributes to progressive ventricular dysfunction. Overexpression of collagen is derived from various sources, including higher levels of fibrogenic growth factors, proliferation of fibroblasts and cellular transdifferentiation. These may be triggered by factors, such as oxidative stress, inflammation, hypertension, cellular senescence and cell death, contributing to age-related fibrotic cardiac remodelling. In this review, we will discuss the fibrogenic contributors in age-related cardiac fibrosis, and the potential mechanisms by which fibrogenic processes can be interrupted for therapeutic intent.

show abstract

“…12 Gal-3 is recognized as a promising new biomarker which has been proved to be effective for diagnosing and evaluating the prognosis of the left heart failure. [13][14][15] The level of Gal-3 was elevated in both idiopathic PAH and connective tissue diseases related to PAH patients 16 ; however, the role of Gal-3 in the PAH-induced right ventricular morphologic changes remains less known.…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 mediates the pulmonary arterial hypertension–induced right ventricular remodeling through interacting with NADPH oxidase 4

Luo

et al. 2017

Journal of the American Society of Hypertension

View full text Add to dashboard Cite

Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction

Abstract: Gal-3 is not able to distinguish between HFrEF and HFpEF patients. However it is related to diastolic dysfunction severity and LV stiffness in HFpEF. Gal-3 demonstrates a prognostic role independently from renal dysfunction in subjects with HFpEF.

Cited by 31 publications

References 36 publications

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Cardiac fibrosis in the ageing heart: Contributors and mechanisms

Galectin-3 mediates the pulmonary arterial hypertension–induced right ventricular remodeling through interacting with NADPH oxidase 4

Contact Info

Product

Resources

About